The interest in field of psychedelic therapy research has recently increased as a potential to help with reducing the crisis for mental health in the world. This project aims to explore the therapeutic potential of novel compounds derived from psilocybin, focusing on their effects within the microbiota-gut-brain axis and interactions with the serotonergic system. By integrating insights from systems psychiatry, we seek to understand the complex mechanisms underlying psychedelic therapy across molecular, cellular, and network levels. The PhD candidate will perform in vivo studies in animal models for depression, will assess pharmacokinetics, toxicity, 5-HT2A receptor binding assay, and alongside will evaluate the modulation of the serotonergic system and microbiota composition. This comprehensive approach aims to advance the development of precision medicine-based treatments for mental health disorders, emphasizing the critical role of the microbiota-gut-brain axis in enhancing the efficacy of psychedelic-like compounds.